Recent Updates
Recently added Catalysts
RDY Positive Sentiment Score: 75/100

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

Key Takeaway: Dr. Reddy's Laboratories Ltd. has established a wholly-owned subsidiary, Dr. Reddy's Laboratories Jamaica Limited, through its Swiss subsidiary. This new entity will engage in importation, warehousing, distribution, and exportation of pharmaceuticals, maintaining alignment with the company’s core business operations. The incorporation followed regulatory approvals, supporting the strategic expansion of Dr. Reddy's into the Jamaican market. The parent company has committed a cash consideration of USD 3,000,000 for full ownership of the new subsidiary.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Reddy's has expanded its global footprint with a new subsidiary in Jamaica.
  • The newly incorporated entity will focus on pharmaceuticals, aligning with Dr. Reddy's core business.
  • The acquisition was made with cash consideration, indicating strong financial backing.
  • The incorporation was completed following necessary regulatory approvals.

Full Press Release Details

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Pursuant to Regulation 30 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended, we hereby inform that Dr. Reddy's
Laboratories SA, in Switzerland, a wholly-owned subsidiary of the Company, has incorporated a wholly-owned subsidiary in Jamaica, named
"Dr. Reddy's Laboratories Jamaica Limited". Accordingly, Dr. Reddy's Laboratories Jamaica Limited is a step-down
wholly-owned subsidiary of the Company.
The details required under Regulation 30 of the SEBI
Listing Regulations, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123
dated July 13, 2023, with respect to the above incorporation of a step down wholly-owned subsidiary is given in Annexure enclosed herewith.
This is for your information and records.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer and Head-CSR
Disclosure under Part A Para A(i) of Schedule III
read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
S. No Particulars Description
1 Name of the target entity, details in brief such as size, turnover etc. Dr. Reddy's Laboratories SA, in Switzerland, a wholly-owned subsidiary of the Company, has incorporated a wholly-owned subsidiary in Jamaica, named "Dr. Reddy's Laboratories Jamaica Limited". Accordingly, Dr. Reddy's Laboratories Jamaica Limited is a step-down wholly-owned subsidiary of the Company. Authorized capital: USD 5,000,000 Paid up capital: USD 3,000,000 Size/Turnover: Not applicable
2 Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length". The NewCo. is a related party of the Company after its incorporation. Save and except as mentioned above, the promoter/ promoter group/ group companies are not interested in the proposed NewCo.
3 Industry to which the entity being acquired belongs. Pharmaceuticals
4 Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) The NewCo. will be engaged in importation, warehousing, distribution and exportation of pharmaceuticals. The business of the proposed NewCo. is not outside the main line of business of the Company.
5 Brief details of any governmental or regulatory approvals required for the acquisition. Not applicable. NewCo. has been incorporated post receiving necessary approvals from Pharmacy Council of Jamaica (PCJ).
6 Indicative time period for completion of the acquisition. Not Applicable
7 Nature of consideration- whether cash consideration or share swap and details of the same. Cash Consideration
8 Cost of acquisition or the price at which the shares are acquired. Dr. Reddy's Laboratories SA will be paying cash consideration amounting to USD 3,000,000 to the proposed NewCo. towards subscription of 100% shareholding.
9 Percentage of shareholding / control acquired and / or number of shares acquired. 100% ownership of Dr. Reddy's Laboratories SA, wholly-owned subsidiary of the Company.
10 Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) The NewCo. will be engaged in importation, warehousing, distribution and exportation of pharmaceuticals. The certificate of incorporation dated September 25, 2023, from the Registrar of Companies, Jamaica, has been received by the Company on September 27, 2023, at 23:51 IST. Further, the said step down wholly-owned subsidiary has been incorporated as a Limited Company, in Jamaica.

Frequently Asked Questions

What is the name of Dr. Reddy's new subsidiary in Jamaica?

The new subsidiary in Jamaica is named 'Dr. Reddy's Laboratories Jamaica Limited'.

What industry does Dr. Reddy's Laboratories Jamaica Limited belong to?

It belongs to the pharmaceuticals industry.

How much capital has been paid for the new subsidiary?

The paid-up capital for the new subsidiary is USD 3,000,000.

Is Dr. Reddy's Laboratories Jamaica Limited a related party?

Yes, it is considered a related party after its incorporation.

What will be the main business activity of the new subsidiary?

The subsidiary will focus on importation, warehousing, distribution, and exportation of pharmaceuticals.

Last updated: Sep 28, 2023